中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (11): 804-806.doi: 10.12144/zgmfskin202411804

• 病例报告 • 上一篇    下一篇

PD-1抑制剂治疗后银屑病复发一例

陈晶1,2*,崔晓晨1,2*,陆继良1,2,周桂芝1,2,吴卫志1,2,杨青1,2   

  1. 1山东第一医科大学附属皮肤病医院，山东济南，250022；2山东省皮肤病性病防治研究所，山东济南，250022 *共同第一作者
  • 出版日期:2024-11-15 发布日期:2024-10-15

Psoriasis recurs after PD-1 inhibitor treatment: a case report

CHEN Jing1,2*, CUI Xiaochen1,2*, LU Jiliang1,2, ZHOU Guizhi1,2, WU Weizhi1,2, YANG Qing1,2   

  1. 1 Hospital for Skin Diseases, Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China *Co-first author
  • Online:2024-11-15 Published:2024-10-15

PDF (PC)

69

摘要： 免疫检查点抑制剂是一类新型的抗肿瘤免疫药物，但因其激活免疫系统，可引发免疫相关不良反应（immune-related adverse events, irAEs），皮肤科irAEs发生率约为40%，包括银屑病、湿疹、白癜风、大疱性疾病、重症药疹及脱发等。本例患者银屑病病史22年，因输尿管癌接受替雷利珠单抗治疗，6周后银屑病复发，遂停用替雷利珠单抗,予口服甲氨蝶呤、外用糖皮质激素软膏和UVB光疗治疗，1个月后皮损大部分消退。随访1年，患者仍有少量银屑病皮损，但外用药物控制良好，且肿瘤未见进展。

关键词: PD-1抑制剂, 替雷利珠单抗, 斑块状银屑病, 免疫相关不良反应

Abstract: Immune checkpoint inhibitors are a new type of anti-tumor immunodrugs, but due to the activation of the immune system, it can cause immune-related adverse events (irAEs). The incidence of irAEs in dermatology is about 40%, including psoriasis, eczema, vitiligo, bullous diseases, severe drug eruptions and alopecia. This patient had a 22-year history of psoriasis and recurred after 6 weeks of treatment with tislelizumab for ureteral cancer. Tislelizumab was discontinued, and the patient was treated with oral methotrexate, topical corticosteroid cream, and UVB phototherapy. Most of the lesions subsided after treatment for 1 month. During 1 year follow-up, psoriasis lesions were well controlled with topical medication, and no tumor progression was observed.

Key words: PD-1 inhibitor, tislelizumab, plaque psoriasis, immune-related adverse